Human papillomavirus vaccination: Good clinical practice recommendations from the Federation of Obstetric and Gynecological Societies of India

Human papillomavirus (HPV) vaccination offers an excellent prospect for the primary prevention of cervical cancer. The bivalent and quadrivalent vaccines are both available in India. The nonavalent vaccine is licensed but not yet available. However, there still remain controversies regarding the vac...

Full description

Saved in:
Bibliographic Details
Published in:The journal of obstetrics and gynaecology research 2020-09, Vol.46 (9), p.1651-1660
Main Authors: Bhatla, Neerja, Meena, Jyoti, Gupta, Krishnendu, Pal, Bhaskar, Divakar, Hema, Bhalerao, Sarita, Peedicayil, Abraham, Srivastava, Shikha, Basu, Partha, Purandare, Chittaranjan Narahari
Format: Article
Language:English
Subjects:
Aged
Alphapapillomavirus
Cervical cancer
Cervix
Clinical medicine
Dosage
Female
Gynecology
HPV vaccination
Human papillomavirus
Humans
Immunization
India
Infant
Obstetrics
Papillomavirus Infections - prevention & control
Papillomavirus Vaccines
Pregnancy
primary prevention
recommendations
Sex crimes
two‐dose
Uterine Cervical Neoplasms - prevention & control
Vaccination
Vaccine efficacy
vaccine hesitancy
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Human papillomavirus (HPV) vaccination offers an excellent prospect for the primary prevention of cervical cancer. The bivalent and quadrivalent vaccines are both available in India. The nonavalent vaccine is licensed but not yet available. However, there still remain controversies regarding the vaccination of older women, immunocompromised females and other special groups. To provide recommendations for HPV vaccination in India. The Federation of Obstetric and Gynecological Societies of India (FOGSI) convened an expert group on cervical cancer prevention to formulate good clinical practice recommendations (GCPR) with respect to vaccine efficacy and safety, target groups, optimal timing and dosing schedules. HPV vaccines are licensed for females aged 9–45 years in India and have been seen to be safe and effective. FOGSI recommends HPV vaccination of all girls 15 years of age, immunocompromised persons and sexual assault survivors. Older women and women with abnormal screening results may be vaccinated with an understanding that vaccination does not protect against already acquired infections and screening has to continue. Single‐dose vaccination results are promising. Increased awareness is required to reduce vaccine hesitancy. HPV vaccination should be the priority to achieve the elimination of cervical cancer. The introduction of affordable HPV vaccines and reduced dose schedules will improve coverage.
ISSN:1341-8076
1447-0756
DOI:10.1111/jog.14345